Loss of protective anti-HBs titers and seroconversion to hepatitis B vaccination in children during chemotherapy for acute lymphoblastic leukemia.
Prasanth Varikkattu RajendranPriyakumari ThankamonyBinitha RajeswariGuruprasad Chellapan SojamaniManjusha NairKusumakumary ParukuttyammaJagathnath Krishna KmPublished in: Pediatric blood & cancer (2022)
HBV boosters helped maintain protective titers during intensive ALL chemotherapy in immunized children having titers more than 10 mIU/L, and more so if titer was more than 100 mIU/L. Therefore, we propose that cut off for protective anti-HBs titers be changed to greater than or equal to 100 mIU/L. Titers between 11 and 100 mIU/L may require combined active and passive immunization. Around one-third of group II patients who fail to attain protective titers may need frequent doses of HBIG.